KISIMA® immunisation platform

KISIMA® immunisation platform

Novel immunisation technology platform

We have developed KISIMA® (‘well’ in Swahili), our first-in-class proprietary immunisation technology platform. The peptide/protein-based vaccination technology is self-adjuvanting and enables the assembly of patented fusion molecules, all essential to generate potent immunity, into one single vaccine.

KISIMA® is highly versatile and we plan to develop vaccines for various cancer indications.

Powerful and highly versatile

KISIMA’s novel immunisation technology enables the assembly of all the components necessary for a potent anti-tumour immune response into one single therapeutic vaccine.

3 components in a one single vaccine

Thanks to this novel proprietary construct, the KISIMA® platform can uniquely and simultaneously provide all the parameters essential for an efficient therapeutic vaccine:

  • Induce helper and cytotoxic T cells
  • Promote immunological memory
  • Target a broad patients population (different antigen and HLA restriction)

KISIMA® immunisation is shown to work in synergy with different immune checkpoint inhibitors in several tumour models.

KISIMA® technology can be used to deliver:

  • tumor-associated antigens
  • neo-antigens
  • modified epitopes 

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL: